Munger M A
College of Pharmacy, Department of Pharmacy Practice, University of Utah, Salt Lake City 84112.
Ann Pharmacother. 1993 Feb;27(2):205-10. doi: 10.1177/106002809302700216.
To review the effects of angiotensin-converting enzyme (ACE) inhibitors on renal pathophysiology and the compensatory mechanisms involved in heart failure. A clinical application of the use of these agents in the setting of concomitant heart failure and renal insufficiency also is presented.
A MEDLINE search was conducted using the terms heart failure, congestive; renal insufficiency; and angiotensin-converting enzyme inhibitors.
All applicable animal and human trials were reviewed.
Advances in the management of heart failure have led to new insights into the complex pathophysiology of this condition, particularly the favorable clinical effects noted with the ACE inhibitors. The net effect of ACE inhibitors on the renin-angiotensin system in patients with heart failure is to augment renal blood flow to a greater extent than cardiac output. Glomerular filtration rate is either unchanged or decreased by ACE inhibition. Sodium excretion is augmented primarily by alterations in glomerular hemodynamic parameters. ACE inhibitors may alter renal tubular function, both directly and indirectly, leading to increased diuresis and natriuresis.
Although ACE inhibitors exert beneficial pharmacodynamic effects on the renal bed in patients with heart failure, clinical consideration of volume and neurohormonal status prior to institution of therapy is prudent.
综述血管紧张素转换酶(ACE)抑制剂对肾脏病理生理学的影响以及心力衰竭中涉及的代偿机制。还介绍了这些药物在合并心力衰竭和肾功能不全情况下的临床应用。
使用心力衰竭、充血性;肾功能不全;以及血管紧张素转换酶抑制剂等术语在医学文献数据库(MEDLINE)中进行检索。
对所有适用的动物和人体试验进行了综述。
心力衰竭管理方面的进展使人们对这种疾病复杂的病理生理学有了新的认识,特别是血管紧张素转换酶抑制剂所具有的良好临床效果。血管紧张素转换酶抑制剂对心力衰竭患者肾素 - 血管紧张素系统的净效应是,其增加肾血流量的程度大于心输出量。肾小球滤过率在血管紧张素转换酶抑制后要么保持不变,要么降低。钠排泄主要通过肾小球血流动力学参数的改变而增加。血管紧张素转换酶抑制剂可直接和间接改变肾小管功能,导致利尿和利钠增加。
尽管血管紧张素转换酶抑制剂对心力衰竭患者的肾床具有有益的药效学作用,但在开始治疗前谨慎考虑血容量和神经激素状态是明智的。